Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

LEXX

Lexaria Bioscience Corp

Nov 08 • 04:00PM ET

2.36

Dollar change +0.04
Percentage change 1.72	%

Healthcare • Biotechnology • Canada • NASD

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	7.72%	Shs Outstand	17.45M	Perf Week	1.72%
Market Cap	41.90M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.07%	Shs Float	16.11M	Perf Month	-22.88%
Income	-	PEG	-	EPS next Q	-	Inst Own	11.77%	Short Float	1.71%	Perf Quarter	-27.83%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	1.80	Perf Half Y	-33.52%
Book/sh	0.64	P/B	3.69	EPS next Y	-	ROA	-	Short Interest	0.28M	Perf Year	50.80%
Cash/sh	0.48	P/C	4.92	EPS next 5Y	-	ROE	-	52W Range	1.20 - 6.85	Perf YTD	88.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.43%	ROI	-	52W High	-65.55%	Beta	1.09
Dividend TTM	-	Quick Ratio	58.27	Sales past 5Y	23.73%	Gross Margin	-	52W Low	96.67%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	58.27	EPS Y/Y TTM	6.34%	Oper. Margin	-2024.38%	RSI (14)	37.93	Volatility	7.31% 7.48%
Employees	5	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	12.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	41.04%	Payout	-	Rel Volume	1.37	Prev Close	2.32
Sales Surprise	-100.00%	EPS Surprise	0.00%	Sales Q/Q	139.90%	Earnings	Jul 19	Avg Volume	153.30K	Price	2.36
SMA20	-7.41%	SMA50	-20.70%	SMA200	-21.61%	Trades		Volume	210,294	Change	1.72%

Nov-07-24 09:15AM	Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments (ACCESSWIRE) +5.94%
Oct-24-24 09:10AM	Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-22-24 09:20AM	Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-16-24 04:00PM	Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
Oct-15-24 08:25AM	Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -6.21%
09:05AM	Loading…
Oct-09-24 09:05AM	Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing (ACCESSWIRE)
Oct-08-24 09:20AM	Lexaria Updates Current GLP-1 Market (ACCESSWIRE)
Oct-01-24 09:25AM	Lexaria Appoints Michael Shankman as Chief Financial Officer (ACCESSWIRE)
Sep-27-24 09:20AM	Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 (ACCESSWIRE)
Sep-05-24 10:00AM	Lexaria Releases Strategic Letter from the Outgoing CEO (ACCESSWIRE)
09:00AM	Lexaria Welcomes Industry Veteran as New CEO (ACCESSWIRE)
Sep-03-24 08:30AM	Lexaria Enters a Material Transfer Agreement for DehydraTECH Research (ACCESSWIRE) -6.65%
Aug-29-24 09:25AM	Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules (ACCESSWIRE) +10.62%
Aug-27-24 09:20AM	First Results from Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Aug-22-24 09:20AM	Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE) -7.90%
09:00AM	Loading…
Aug-21-24 09:00AM	Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Aug-19-24 09:05AM	Positive Results from Lexaria's Molecular Characterization Study (ACCESSWIRE)
Jul-17-24 10:30AM	Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study (ACCESSWIRE)
Jul-16-24 09:20AM	Lexaria Preparing For Strategic Growth (ACCESSWIRE)
Jul-12-24 05:52PM	LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024 (InvestorPlace)
Jul-09-24 09:10AM	Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jul-08-24 09:10AM	Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy (ACCESSWIRE) -5.49%
Jun-24-24 06:40AM	7 A-Rated Penny Stocks to Beat June Gloom (InvestorPlace)
Jun-18-24 09:00AM	Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study (ACCESSWIRE)
Jun-14-24 07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace) -6.08%
Jun-05-24 09:00AM	Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-30-24 06:45AM	7 A-Rated Penny Stocks Work Betting On in H2 2024 (InvestorPlace) +5.00%
May-23-24 09:05AM	Lexaria Awards Contract For Third GLP-1 Human Pilot Study (ACCESSWIRE)
May-21-24 09:20AM	Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy (ACCESSWIRE)
09:10AM	Loading…
May-17-24 09:10AM	Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study (ACCESSWIRE)
May-08-24 09:10AM	Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study (ACCESSWIRE)
May-06-24 09:05AM	Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs (ACCESSWIRE) +8.95%
Apr-30-24 03:40PM	Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance (ACCESSWIRE) +25.61%
Apr-16-24 09:10AM	Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study (ACCESSWIRE) +16.08%
Apr-09-24 09:52PM	LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024 (InvestorPlace) -8.78%
Apr-02-24 09:00AM	Lexaria Awarded New Patents (ACCESSWIRE)
Mar-21-24 09:20AM	Lexaria to Present at The LD Micro Invitational XIV (Newsfile) -7.03%
Mar-14-24 09:20AM	Lexaria Appoints Nelson Cabatuan as Chief Financial Officer (ACCESSWIRE) -12.50%
Mar-07-24 09:05AM	Lexaria Awards Contract For Next GLP-1 Human Pilot Study (ACCESSWIRE) +11.61%
Mar-05-24 09:05AM	Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 (ACCESSWIRE) +12.67%
Mar-04-24 09:15AM	7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study (ACCESSWIRE)
Mar-01-24 08:20AM	Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial (ACCESSWIRE) -15.36%
Feb-16-24 04:05PM	Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.32% +8.41%
Feb-15-24 08:00AM	Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.23%
Jan-30-24 08:45AM	Lexaria's Submits Investigational New Drug Application (ACCESSWIRE)
Jan-24-24 08:45AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Jan-22-24 08:51AM	LEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024 (InvestorPlace)
Jan-16-24 09:10AM	Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program (ACCESSWIRE)
Jan-11-24 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream (GlobeNewswire) +5.56%
Jan-10-24 08:30AM	GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons (PR Newswire)
Jan-09-24 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform (GlobeNewswire)
Jan-08-24 08:30AM	Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs (PR Newswire)
Jan-04-24 09:05AM	Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide (ACCESSWIRE) +6.92%
Dec-07-23 09:20AM	Lexaria's Investigational New Drug Application Filing Update (ACCESSWIRE)
Nov-28-23 09:10AM	Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study (ACCESSWIRE)
Nov-27-23 09:05AM	Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study (ACCESSWIRE) +24.43%
Nov-01-23 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space (GlobeNewswire) +5.07%
08:30AM	Get Ready for Next Generation of Diabetes, Weight-Management Drugs (PR Newswire)
Oct-31-23 08:31AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs (GlobeNewswire)
Oct-30-23 09:30AM	Can Diabetes, Weight-Loss Drugs Get Even Better (PR Newswire) +14.66%
Oct-13-23 09:05AM	Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn (ACCESSWIRE) -6.61%
Oct-12-23 09:10AM	Lexaria Granted Two New Patents in Canada (ACCESSWIRE)
Sep-29-23 08:00AM	Lexaria Announces Pricing of $1.6 Million Registered Direct Offering (ACCESSWIRE)
Sep-21-23 09:10AM	Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD (ACCESSWIRE)
Aug-30-23 09:20AM	Lexaria Provides Update on Investigational New Drug Application Progress (ACCESSWIRE)
Aug-28-23 09:02AM	LEXX: 3Q:23 Financial Results & Corporate Updates (Zacks)
Aug-23-23 11:12AM	Lexaria Bioscience Corp: A Comprehensive Stock Price Change Analysis (GuruFocus.com)
Aug-09-23 09:15AM	Lexaria's DehydraTECH-Nicotine Faster than ZYN and on! (ACCESSWIRE) +6.81%
Aug-02-23 09:10AM	Lexarias Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD (ACCESSWIRE)
Jul-28-23 09:10AM	Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study (ACCESSWIRE)
Jul-19-23 09:05AM	Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products (ACCESSWIRE)
Jun-26-23 07:47AM	LEXX: A Little Bit of Everything (Zacks Small Cap Research)
Jun-22-23 09:25AM	Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science (ACCESSWIRE) +8.51%
Jun-20-23 09:05AM	Lexaria Receives New Patents (ACCESSWIRE)
Jun-16-23 09:10AM	Lexarias DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study (ACCESSWIRE)
Jun-12-23 09:20AM	Lexaria Appoints New Chief Financial Officer (ACCESSWIRE)
May-23-23 09:05AM	Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers (ACCESSWIRE) +13.21%
May-18-23 04:22PM	Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH (Benzinga) +19.60% -14.94%
09:05AM	Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery (ACCESSWIRE)
May-11-23 01:45PM	Lexaria Bioscience Announces Closing of $2.0 Million Public Offering (ACCESSWIRE)
09:00AM	cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial (ACCESSWIRE)
May-10-23 10:15AM	Lexaria Announces 2023 Annual Meeting Results (ACCESSWIRE)
May-08-23 08:35PM	Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering (ACCESSWIRE) -21.76% -22.92%
09:05AM	Lexarias Human Clinical Nicotine Study Completes Dosing as Planned (ACCESSWIRE)
Apr-24-23 09:00AM	Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study (ACCESSWIRE)
Apr-20-23 09:00AM	Lexaria is Receiving Four New Patents (ACCESSWIRE)
05:40AM	LEXX: DehydraTECH CBD May Offer New Mechanism of Action (Zacks Small Cap Research)
Mar-07-23 05:54AM	Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Mar-02-23 08:45AM	Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels (ACCESSWIRE)
Feb-21-23 02:41PM	Lexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBD (Benzinga)
09:00AM	Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4 (ACCESSWIRE)
Jan-31-23 08:30AM	Lexaria Bioscience: Charting a Path to Commercial Success (NewMediaWire)
Jan-23-23 08:45AM	Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor (ACCESSWIRE)
Jan-17-23 08:33AM	LEXX: DehydraTECH: Developing Diabetes and Dementia (Zacks Small Cap Research)
Jan-13-23 04:05PM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Dec-29-22 09:00AM	Lexaria Receives First Granted Patent in Canada (ACCESSWIRE)
Dec-21-22 09:00AM	Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels (ACCESSWIRE) +5.60%
Dec-20-22 12:35PM	Lexarias Human Oral Nicotine Study Begins Dosing (ACCESSWIRE)
Nov-30-22 05:24AM	Lexaria Bioscience Full Year 2022 Earnings: Misses Expectations (Simply Wall St.) +9.63%

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TURKEL CATHERINE C.	Director	Aug 12 '24	Buy	3.13	1,600	5,008	3,100	Aug 13 10:55 AM
Carle Vanessa	Secretary	Jul 31 '24	Sale	4.00	2,567	10,268	0	Aug 01 12:25 PM
Carle Vanessa	Secretary	May 14 '24	Option Exercise	1.15	2,500	2,875	2,567	May 15 05:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LEXX

Lexaria Bioscience Corp

Upgrade your FINVIZ experience